| FSE

Fresenius Kabi today announced the immediate availability of two drugs in the United States. The first product, Gadobutrol Injection, a gadolinium-based contrast agent for used in MRIs.¹ It is the latest addition to Fresenius Kabi’s new radiology portfolio that offers hospitals a range of cost-effective contrast agents. The second product, Plerixafor Injection, a hematopoietic stem cell mobilizer is the newest addition to the company’s large generic injectable oncology medicine portfolio.

¹ Gadobutrol Injection Package Insert, January 2023

Fresenius Kabi and Formycon have entered into a settlement agreement with Johnson & Johnson concerning FYB202, a proposed Ustekinumab biosimilar in the United States. Subject to regulatory approval, the settlement grants an entry date for FYB202 in the United States no later than April 15, 2025.

FYB202 is an Ustekinumab biosimilar candidate that references Johnson & Johnson’s Stelara®*, a human monoclonal antibody for the treatment of immune-mediated disorders.

* Stelara® is a registered trademark of Johnson & Johnson

The Health Care Group addition

Stories addition

Investors addition

Media addition

Berenberg & Goldman Sachs – 12th German Corporate Conference

Baader Investment Conference

Goldman Sachs – 20th Annual European Medtech and Healthcare Services Conference

Commerzbank and ODDO BHF’s Corporate Conference 2023

Quarterly Financial Report Q2 2023 (IFRS)

Roadshow London